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Original Article
Renal Involvement in Systemic Lupus Erythematosus in Pakistan
Malik Anas Rabbani, Muhammad Hammad Tahir, Bilal Karim Siddiqui, Bushra Ahmad, A Shamim, 
Syed Mansoor Ahmed Shah, Aasim Ahmad
Department of Medicine, The Aga Khan University Hospital, Karachi.
Abstract
Objective: To find the prevalence of lupus nephritis, delineate its clinical, immunological and therapeutic charac-
teristics and compare them with the data worldwide. 
Patients and Methods: Between 1985 and 2001, 198 patients with SLE fulfilling the clinical and laboratory cri-
teria of the American Rheumatism Association (ARA) admitted to the hospital were studied by means of a retro-
spective review of their records. 
Results: Renal involvement was found in 89 (45%) patients. Biopsy showed lupus nephritis in 42 patients; there
were 9 male and 33 females. Mean age at initial presentation was 27 years and mean duration of follow-up was
2 .3 years. The histological types (WHO Classification) were mainly class. 4 (n=27), class 3 (n=7) and class 5
(n=6). Immunoflourescence showed a predominantly granular pattern of IgG, IgA and C3. Renal manifestations
included renal failure (50%), microscopic hematuria (67%), active urine sediment (22%), and proteinuria (74%).
Proteinuria was nephrotic range in 45% patients. Treatment was with combinations of prednisolone and
cyclophosphamide (n=13), prednisolone and azathioprine (n=27). 19 patients received high dose methyl pred-
nisolone (1 gm/day for 3 days).  There was no difference in mortality rate between prednisolone and cyclophos-
phamide and prednisolone and azathioprine treatment groups. The overall mortality rate was 17% (n=7). Mortality
was higher in WHO class 4 and 5 as compared to class 2 and 3 (p<0.001). 
Conclusion: The prevalence of lupus nephritis in our population is an intermediate between Caucasians and
other Asians. Certain clinical characteristics in our patients with lupus nephritis are different as compared to var-
ious other studies. Because of limited resources for treatment in developing countries, we believe that patients
with lupus nephritis should be treated with improved ancillary medical therapies and more effective immunosup-
pressive regimens (JPMA 55:328;2005).
Introduction
Systemic Lupus Erythematosus is no longer an exot-
ic disease in many communities. It is becoming a frequent-
ly diagnosed condition possibly due to increased awareness
of the protein manifestations and the availability of serolog-
ical markers.
Renal involvement is a serious feature of systemic
lupus erythematosus (SLE), occurring in 40-75% of these
patients.1,2 Despite great improvement in the management
of lupus nephritis, it remains the most frequent cause of
SLE-related mortality.2
The incidence and severity of lupus nephritis may be
related to the patients' racial background3, and studies have
suggested the presence of nephropathy susceptibility genes
predisposing to lupus nephritis.1
Lupus Nephritis remains a major cause of morbidity
and mortality4 particularly among patients of Hispanic5 and
African-American ethnicity6 SLE patients with renal
involvement are at a higher risk of dying of this disease.7,8
Generally renal involvement is more common in Blacks9
Indians10 and Chinese11, with lesser prevalence in
Caucasians11 and Arabs.12,13
Data on the characteristics of SLE in Pakistan seems
somewhat scarce. The main purpose of this study was to
review clinicolaboratory features of lupus nephritis in
Pakistan and to compare it with those previously reported in
other populations.
Patients and Methods
Between 1985 and 2000, 198 patients with SLE ful-
filling the clinical and laboratory criteria of the American
Rheumatism Association admitted to the hospital, were
studied by means of a retrospective review of their records.
Of these patients, 79 (40%) were admitted through outpa-
tient clinics and rest through emergency department. Of
these 198 patients, renal involvement (defined as Raised
Serum Creatinine (>1.3 mg/dl), persistent proteinuria >0.5
g/day or presence of active cellular casts) was found in 89
(45%). However biopsy was not performed in all the cases,
and there were only 43 cases of biopsy proven lupus nephri-
tis. Patients with renal involvement were compared with
those without it by chi square test and odds ratios were
determined using 95% CI. Patients were analyzed according
to their clinical symptoms and laboratory profile which
included complete blood counts, serum creatinine and elec-
trolytes, ESR, total proteins, 24 hour urinary proteins, crea-
tinine clearance, anti nuclear factor, anti-DNA, Rheumatoid
factor, serological test for syphilis, serum compliment lev-
els, anti-ENA, chest x-ray, ultrasound kidneys and echocar-
diogram. Renal histological assessment 
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was performed by light microscopy and immunoflu-
orescence studies. The World Health organization (WHO)
classification of lupus nephritis2, viz. class 1 normal or min-
imal disease, class 2 mesangial disease, class 3 focal prolif-
erative glomerulonephritis, class 4 diffuse proliferative
glomerulonephritis and class 5 membranous nephropathy,
was used. The treatment was analyzed and divided into
those patients who received prednisolone and azathioprine
and the other group who received prednisolone and
cyclophosphamide. The dose of prednisolone was initiated
at 1 mg/kg of body weight and was maintained for 4-6
weeks. This was lowered gradually to a maintenance dose
of 7.5-10 mg/day, once a remission was obtained.
Azathioprine and cyclophosphamide were started at doses
of 1 mg/kg of body weight and were gradually increased to
2 mg/kg of body weight (max.). Mean duration of treatment
with AZA was 36 months where as with cyclophosphamide
it was 12 months. To assess response to therapy following
parameters were assessed.  
*     Improvement in renal function (decreased in serum 
creatinine, improvement in Creatinine - Clearance).
*     Decrease in degree of proteinuria.
*     Normalization of lupus serology (Anti ds DNA, 
Serum compliment levels).
For data analysis, statistical package for social sci-
ence, SPSS (Release 10.0.5, standard version, 1989 - 99)
was used. Univariate analysis and Fischers Exact test were
used for statistical analysis. 
The results were compared with various internation-
al studies. For comparing studies Chi square tests were used
and Odds Ratio (OR) were calculated with 95% Confidence
Intervals.
Results
There were total of 198 patients with SLE fulfilling
the clinical and laboratory criteria of the American
Rheumatism Association. Of these 89 (45%) had renal
involvement by ARA criteria.
A comparison by Univariate analysis (Table 1) found
BM suppression and serositis were significantly more in
those with renal involvement. Presence of malar rash was
significantly less in this group. Although males had higher
odds of having renal involvement, but it failed to reach a
statistical significance. Mortality Rate was higher in those
with renal involvement.
Forty two patients had biopsy proven lupus nephri-
tis. Of these, 9 were male and 33 were females. Mean age at
initial presentation was 27 years and mean duration of fol-
low-up was 2.3 years. 
The commonest presenting symptoms were fever,
musculoskeletal and mucous membrane involvement. Fever
was present in 16 (38%) arthritis in 12 (28%) and oral ulcers
in 12% patients. Skin involvement occurred in 27 patients
(76%) and included malar rash (26%), photosensitivity
(4%), discoid rash (17%) and alopecia (17%).
Other manifestations included central nervous system
(CNS) involvement in 9 patients (n=21%), seen as seizures in 3,
psychosis in 4 and CNS infarctions in 2 patients. 48% of the
patients were hypertensive at the time of presentations. 
Infections occurred in 48% patients (n=20). These con-
sisted of respiratory tract infections in 14% patients, urinary
tract infections in 26%, CNS infections 2%, skin infections or
cellulitis 14%, thrush in 5% and septicemia with DIC (dissem-
inated intravascular coagulation) in 12%. The commonest
pathogens were E.coli   (17%), Klebsiella (9%), 
Table 1. Univariant analysis between those with renal involvement and those without it.
Renal involvement (%) No Renal involvement (%) P value OR       (95% CI)
Female 42.5 67.5 0.065 0.44  (0.18-1.07)
Male 62.5 37.5
No Bone marrow suppression 42.7 57.3 0.017 0.224 (0.06-0.84)
Bone Marrow suppression 76.9 23.1
Malar rash 33 67 0.030 0.50 (0.266-0.941)
No malar Rash 50 50
Serositis 59 41 0.033 2.08 (1.05-4.12)
No Serositis 40.9 50.1
<3 hospitalizations 41 59 0.013 0.38 (0.17-0.83)
>3 hospitalizations 65 35
Dead 65 35 0.010 2.75 (1.24-6.07)
Alive 40.5 59.5
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Pseudomonas (7%),  Staphylococcus areus (5%), and
Candida albicans (3%).
Lymphoreticular involvement occurred in 14%
patients and consisted of lymphadenopathy in 3%, hepato-
splenomegaly in 11%. Cardiac involvement was encountered
in 8% patients and consisted of pericarditis in 5%, myocardi-
tis in 3% and 19% had pleural effusion.
Of the hematological involvement, 69% had anemia
(Hb<11 gm/dl), 21% patients developed leukopenia
(WBC<4x109/L), 21% thrombocytopenia (platelets
<150x109/L), 48% lymphopenia and 12% developed pancy-
topenia. Hemolytic anemia was present in 3% patients. Deep
vein thrombosis, pulmonary embolism and abortions did not
occur in any patient. Two patients had family history of sys-
temic lupus erythematosus.
Laboratory Data 
Renal Function and Investigations
Fifty percent patients had elevated serum creatinine
(normal <1.3 mg/dl). Mean serum creatinine at presentation
was 2.48mg/dl (range 0.4-16.60 mg/dl). Mean serum Cr in
Class 4 was 2.49mg/dl (St. Dev +3.33), in Class 5, 1.5mg/dl
(St Dev. +1.53) and Class 3, 2.7mg/dl (St. Dev. +4.32).
Seventy percent patients had proteinuria at presenta-
tion (Table 3). Mean protein excretion in urine at presentation
was 3.6 grams/24 hours (range 11-12800 mg/day). Of these,
45% had nephrotic range proteinuria, 67% patients micro-
scopic hematuria and 22% active urine sediments at presen-
tation. 
Renal Histology
The indications for renal biopsy were proteinuria (+1
to +4 on albustix testing) or active urinary sediment (red
blood cell, granular cast, broad cast in a urine specimen) and
renal failure (Serum Cr. >1.3 mg/dl). There were 27 patients
with WHO class 4, 7 with class 3, 6 with class 5 and 3
patients with class 2.
Immunofluorescence studies 
Sixty percent patients were positive for IgG, 20% for
IgA, 15% for IgM and 20% for C3.
Treatment
Various treatment combinations used were, pred-
nisolone and cyclophosphamide (n=13), prednisolone and
azathioprine (n=27) whereas 19 patients received methyl
prednisolone. Cyclosporine and chlorambucil were used in
one patient each.
Follow-up
Forty percent patients were lost to follow-up. In-hos-
pital mortality was 17% in patients who did not undergo renal
biopsy (16% in biopsy group). The main cause of death 
Table 2. Univariant analysis for risk factors of mortality in biopsy proven
Lupus Nephritis.
Dead (%) Alive (%) P value OR       (95% CI)
Infection 35 65 0.003 2.69 (1.75-4.14)
None 0 100
Neurological 43 57 0.07 5.8 (0.94-36.0)
involvement
None 6 94
Alopecia 56 44 0.009 0.07 (0.01-0.47)
None 08 92
(Fischers Exact test used in all, because of small n).
Table 3. Differences in Autoantibodies, Complement Levels and Renal Function abnormalities between various countries and Pakistan.
Pakistan  Lebanon14 China11 UAE12 Belgrade8 Thailand23 
n= 43, n (%) n=50, n (%) n=180, n (%) n=21 n=58 n=568
ANA 26 (79) 45 (90) 16 (94) 55 (95)
Anti dsDNA 25 (74) 40 (80) 126 (69) 21 (100) 42 (72.2)
Low C3 36 (86) 30 (60)* 136 (74) 12 (60)
Raised Serum 21 (50) 16 (32) (25) (46)
Creatinine
Proteinuria 31 (74) 46 (92)
Nephrotic range  23 (55) 13 (26) 61(34) (41.3)
Non-Nephrotic range   08 (19) 33 (66)
Active Urinary  Sediment   37 (88) 23 (46)
331 J Pak Med Assoc
was infections (86%) and CNS involvement (14%)
(Table 2). The infections were mainly of urinary tract and
chest. When cyclophosphamide and azathioprine groups
were compared at the end of 2 years follow-up, no difference
was noted in the mortality rate. Analysis of data further
revealed that mortality rate was higher in WHO class 4 and 5
(18%) as compared to class 2 and 3 (11%) (p<0.001).
It is difficult to evaluate Renal-Survival considering
the significant number of patients lost to follow-up. Of
those the who continued to come, only two patients devel-
oped ESRD requiring dialysis. Both of these patients
received cyclophosphamide.
As far as the prognostic factors are concerned, renal
involvement was the single most important predictor of poor
outcome. However despite this there was no difference in
mortality in those who presented with higher serum Cr values
as compared to those with relatively lower serum Cr values. 
Discussion
Lupus Nephritis as an entity has not been studied
before in Pakistan. Literature on SLE in Pakistan is scarce.
Cutaneous manifestations of lupus in Pakistani patients
have been presented by Rabbani et al15 and another study by
Suleman et al16 discussed the relevance of classification set
forth by American Rheumatology Association to local lupus
patients. We believe that under reporting of lupus in
Pakistan has given ground to the false belief that SLE is not
a common disease in Pakistan. The true frequency of SLE,
however, can only be obtained by conducting a community-
based study. 
It is known that lupus nephritis has a higher prevalence
in Indians10, Chinese11 and Blacks9 than Caucasians.11
Paradoxically, our study showed a lower prevalence
of renal involvement (45%) as compared to the Indians
(73%)10, Blacks (78%)19, Chinese (54%)11 and Arabs12
(54%). This suggests that the prevalence of renal involve-
ment in our population is intermediate between Asian and
Caucasians (39%).
We found lower frequency of malar rash in patients
with lupus nephritis. In contrast, Anay J M et al17, in a
cross-sectional multicenter study in Colombia observed that
patients who developed nephritis had a higher frequency of
oral ulcers (41% vs. 21%, OR = 3.1, 95% CI: 1.3-7.5 p =
0.01) and malar rash (77% vs. 45%, OR = 4.4, 95% CI: 1.8-
10.8, p<0.001). Our study also shows that patients with
renal involvement are high risk group in SLE as there were
significantly more deaths in them which is consistent with
many other studies.7-8 The overall mortality rate in our
study was 17% which is higher than other studies world-
wide.12 We believe that actual mortality rate is much higher
in our patients than what is reflected by our study as many
of the patients are lost to follow-up as suggested by mean
follow up period of less than 3 years.
The male to female ratio in those with biopsy proven
SLE was lower than Arabs12, Americans and Orientals.23
Mean age, however was consistent with other studies12, The
main histological types were WHO class 3 (17%), class 4
(64%) and class 5 (14%). This study also revealed that we
had the highest prevalence of WHO histological class 4 as
compared to Indians, Orientals, Blacks, Africans, Arabs,
Americans and Europeans.12 A higher prevalence of Grade
III lesion is seen in the Chinese population11 which may
suggest that there is some genetic component which deter-
mines the type of renal lesion. However higher prevalence
of Class 3 and 4 may also be due to the fact that renal biop-
sy was done in selective cases.
Univariate analysis by Fischer's Exact test showed
higher mortality in those with alopecia and infections. All
those who died had underlying infections. A Chinese
study11 also found that most of their deaths were due to
infections. It seems that increased risk of acquiring infec-
tions was associated with aggressive immunosuppression
therapy used in class 4 and 5 that lead to bone marrow-sup-
pression and overwhelming sepsis. It is important to note
that all patients who developed marrow suppression due to
immunosuppressive agents invariably developed infections.
Bone-marrow suppression secondary to immunosuppres-
sion was defined as leukopenia or thrombocytopenia or
both, warranting reduction of dose of the immunosuppres-
sive drug. In all patients the status of leukopenia and throm-
bocytopenia had been confirmed by repeated complete
blood counts. The cytotoxicity of immunosuppressive drugs
was confirmed by clearly improving blood pictures follow-
ing reduction of the respective doses of CYC and AZA. 
Immunosuppressive regimens, at present, mainly
rely on western guidelines that were derived from studies
conducted in western populations. Unfortunately, no such
study exists for South Asian population, which is home to
over one billion people, different in both genetics and envi-
ronment from west. Locally derived thresholds markedly
differ from western figures.24 This may warrant re-adjust-
ment of current local immunosuppressive regimens that are
at present based largely on western guidelines. 
Studies have shown that auto antibodies may play a
role in pathogenesis of lupus nephritis. High-titer antibodies
to dsDNA, for example, have been identified in lupus
nephritis and their levels tend to rise and fall with the dis-
ease.13 This widely recognized correlation has been report-
ed in several populations of lupus patients including
Caucasians18, Afro-Caribbeans19 and Asians.10 Studies have
shown that DNA-anti dsDNA antibody complexes indeed 
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participate in the pathogenesis of lupus nephritis.
When autoantibody profile in biopsy proven lupus nephritis
was compared to various studies, ANA was found to be
lower12 but there was no difference in the prevalence of anti
dsDNA.12 However we could not find any correlation
between anti dsDNA titers with nephritis.
Serum complement abnormalities tend to parallel the
activity of lupus nephritis.19 Persistent depression of C3
complement has been associated with progression of kidney
disease in some, but not all, groups of patients.19 Declining
C3 or C4 are predictors of exacerbations of lupus nephritis.
Occurrence of high-grade proteinuria has not emerged as a
consistent predictor of renal failure in patients with lupus
nephritis.20 In our patients there was a higher incidence of
C3 hypocomplementenemia and nephrotic range protein as
compared to various studies worldwide.12 
In our study there was no difference in the 2 modal-
ity groups (prednisolone/azathioprine and
prednisolone/cyclophosphamide). Intravenous pulse
cyclophosphamide is shown to be superior in terms of effi-
cacy and survival in many studies.21,22 However our experi-
ence in local population has shown that it is associated with
high rates of mortality secondary to severe bone marrow
suppression and serious infections.
Conclusion
This is the first study on lupus nephritis in Pakistan.
We have found that the prevalence of lupus nephritis in our
population is an intermediate between Caucasians and other
Asians. It was seen that certain clinical characteristics in our
patients with lupus nephritis have different prevalences as
compared to various other studies.
In conclusion lupus nephritis in Pakistan is associat-
ed with high rate of morbidity and mortality. The WHO
classification of lupus nephritis as judged by our experience
does give some idea about prognosis. Serious infections
associated with aggressive immunosuppression used in
class 4 and 5 are the main cause of mortality. We therefore
recommend that our local lupus patients not only need
improved ancillary medical therapies and readjusted
immunosuppression regimens according to local thresholds
but also closer monitoring and follow-up, particularly seek-
ing and treating infections vigorously. 
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